Efficiency and Safety of Nasal Positive Airway Pressure Systems During Endoscopic Procedures in High Risk Patients. Endo-Breath-Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hypercapnia
- Sponsor
- University of Ulm
- Enrollment
- 98
- Locations
- 1
- Primary Endpoint
- Incidence of Hypoxia ( SpO2 < 90%, lasting longer than 10 seconds) during the endoscopic procedure
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Goal of our study is to investigate whether the implication of nasal positive airway pressure (nPAP) system on patients with high periprocedural risk could significantly lower the incidence of severe hypoxia and hypercarbia. Furthermore, we have set up goals to assess key components and factors, which lead to development of hypercarbia during endoscopy.
Detailed Description
Sedation of high-risk patients resemble a relevant issue in interventional endoscopy. This especially because standard oximetric monitoring displays only hypoxia and not the preceding hypercapnia. Therefore, the question arises whether the implication of a nasal positive airway pressure (nPAP) system can decrease the rate of sedation associated events. The Null Hypothesis: The incidence of hypoxia in interventional group, using nasal positive airway pressure system, in comparison to control group with conventional oxygen supplementation canula is not significant. Alternative Hypothesis: The incidence of hypoxia in interventional group, using nasal positive airway pressure system is significantly lower, than in a control group with conventional oxygen supplementation canula
Investigators
Thomas Seufferlein
Prof. Dr. med. Benjamin Walter
University of Ulm
Eligibility Criteria
Inclusion Criteria
- •ASA III (poorly controlled Diabetes Melitus (DM) or arterial hypertension (HTN), Chronic obstructive Pulmonary Disease (COPD), morbid obesity (BMI≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, End Stage Renal Disease (ESRD), Advanced Liver Disease ( ACLD) ; history (\>3 months) of Myocardial Infarction, coronary artery disease (CAD) , transient ischemic attack (TIA), or CAD/stents)
- •ASA IV (recent (\<3 months MI, CVA, TIA, or CAD/stents, ongoing cardiac ischemia or severe valve dysfunction, severe reduction of ejection fraction, sepsis, ARD or ESRD not undergoing regularly scheduled dialysis
- •Active Malignancy (ECOG Performance \>2)
Exclusion Criteria
- •Patients with tracheotomy
- •Pregnancy
- •Intubation assisted endoscopy
- •Procedure without sedation
Outcomes
Primary Outcomes
Incidence of Hypoxia ( SpO2 < 90%, lasting longer than 10 seconds) during the endoscopic procedure
Time Frame: During endoscopic procedure
Incidence of severe Hypoxia ( SpO2 < 80%, lasting longer than 10 seconds) during the endoscopic procedure
Time Frame: During endoscopic procedure
Secondary Outcomes
- Interception of the intervention due to insufficient oxygenation(During endoscopic procedure)
- The emmergence of serious adverse events(During endoscopic procedure)
- Difference of delta tcpCO2 (transcutaneous pCO2) levels between two groups(During endoscopic procedure)
- Number of desaturation episodes (SpO2 < 90%)(During endoscopic procedure)